Table of Contents

5-Lipoxygenase.- LTC4 synthase: A key enzyme in cysteinyl leukotriene formation.- Leukotriene A4 hydrolase: A key enzyme in chemotactic leukotriene formation.- Metabolism of leukotrienes and formation of new leukotriene structures.- Receptors for cysteinyl-leukotrienes: Targets for new drugs.- Targeted disruption of 5-lipoxygenase.- Transcellular biosynthesis of leukotrienes: A unique mode of cell communication.- Physiological and pathophysiological activities of leukotrienes.- Entry rate and metabolic handling of LTC4 in the human circulation.- Genetic polymorphisms of 5-LO.- Leukotrienes and aspirin-intolerant asthma.- Leukotrienes in nocturnal asthma.- Leukotrienes and allergic asthma.- Inhibitors of leukotrienes: An overview.- The development of zafirlukast (Accolate®) and the Zeneca series of peptidyl-leukotriene receptor antagonists.- The development of zileuton (ZYFLO®) and the N-hydroxyurea class of 5-lipoxygenase inhibitors.- The development of BAY X 1005 and the Bayer series of leukotriene biosynthesis inhibitors.- The development of iralukast: A member of the Novartis series of cysteinyl leukotriene antagonists.- LTB4 receptor antagonists.- SmithKline Beecham pharmaceuticals’ cysteinyl leukotriene receptor antagonists: Pranlukast (SB 205312; Ono-1078; Onon), Pobilukast (SK&F 104353) and SK&F 106203.